FIGURE 4. Therapeutic reduction of lipoprotein and cholesterol levels after siRNA treatment.
From the following article:
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek, Akin Akinc, Birgit Bramlage, Klaus Charisse, Rainer Constien, Mary Donoghue, Sayda Elbashir, Anke Geick, Philipp Hadwiger, Jens Harborth, Matthias John, Venkitasamy Kesavan, Gary Lavine, Rajendra K. Pandey, Timothy Racie, Kallanthottathil G. Rajeev, Ingo Röhl, Ivanka Toudjarska, Gang Wang, Silvio Wuschko, David Bumcrot, Victor Koteliansky, Stefan Limmer, Muthiah Manoharan and Hans-Peter Vornlocher
Nature 432, 173-178(11 November 2004)
doi:10.1038/nature03121
a, Lipoprotein profile of pooled plasma samples from treatment groups determined by NMR analysis. b, Relative reduction of lipoprotein classes for the siRNA treatment groups normalized against the average levels of saline control group. c, Effects of siRNA administration on plasma cholesterol and LDL cholesterol. Plasma cholesterol was determined by enzymatic assay and LDL cholesterol calculated from NMR measurements. Error bars represent the s.d. of the mean. Statistical analysis was by ANOVA with Bonferroni post-hoc t-test, one-tailed. Asterisk, P < 0.0001 compared with saline and chol-mismatch-siRNA control animals. NMR data are based on single measurements of pooled plasma from treatment groups.